{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-060563","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2025-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.096372+00:00","generated_at":"2026-05-23T02:08:45.496402+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Larimar Q1 net loss $29.3M; FDA open to accelerated approval using skin FXN as surrogate endpoint","bullets":["Net loss $29.3M ($0.46 per share) vs $14.7M ($0.27) YoY; R&D spend rose to $26.6M on manufacturing and Phase 3 prep.","Cash, equivalents and marketable securities $157.5M as of March 31, 2025; runway into Q2 2026.","FDA agreed to consider skin FXN concentration as reasonably likely surrogate endpoint for accelerated approval.","BLA submission planned by year-end 2025; global Phase 3 study to begin mid-2025 with U.S. and international sites.","Adolescent PK run-in dosing completed; 50 mg OLE and adolescent data expected in September 2025 program update."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-060563","json":"https://secwatch.observer/filing/0000950170-25-060563.json","markdown":"https://secwatch.observer/filing/0000950170-25-060563.md","text":"https://secwatch.observer/filing/0000950170-25-060563.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000095017025060563/0000950170-25-060563-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000095017025060563/lrmr-20250430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T02:08:45.496402+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}